Board of Directors

Stéphane Verdood – Non-executive Director; Chairman of the Board

Stéphane Verdood, Vesalius Biocapital Partners s.à. r.l., has 25 years’ experience as a business consultant in the healthcare, pharmaceutical and biotechnology industries. Mr. Verdood worked for more than 15 years at Arthur Andersen in the areas of business consulting and pharmaceutical industry. He successfully merged and reorganized hospitals in Europe and re-engineered European pharmaceutical companies in the areas of R&D, distribution and sales.

Stéphane founded Andersen Business Consulting in Belgium in 1995. He co-founded Value for Growth in 2001 as venture coach of mainly young biotechnology companies. He assisted in more than 10 start-up companies in fundraising. Mr. Verdood holds a M.Sc. in commercial engineering as well as an MBA from the University of Leuven.

Keith F Martin, PhD, MIoD, MRPharmS – Chief Executive Officer

Keith Martin has enjoyed a successful 30+ year career in both large pharmaceutical companies and early stage biopharmaceutical companies. He has held senior positions in R&D and corporate & business development as well as both executive and non-executive Board positions with management and leadership roles in UK, Belgium, USA & Spain. He has raised more than € 40 million in equity and grants for early stage companies. In addition, Keith has developed products from bench to market and realised value through significant licensing deals as well being experienced in venture investment.

Since April 2006, he has been CEO of Apitope. He led the completion of two successful Phase I clinical trials in multiple sclerosis patients, closed the €10 million Series A (October 2008) and €12 million Series B (September 2015) financings and a €150 million+ licensing deal in January 2009.

Previously as a founder and president of KetoCytonyx Inc, he was responsible for securing seed and Series A financing of €4.6 million. Prior to that role, as BTG’s Global Director of Life Sciences, he was responsible for an extensive portfolio of product candidates and licensee marketed products. As Deputy Head of Biology at BASF Pharma, he developed six CNS compounds from the bench through to Phase I and was a key member of the team that developed two products to full market approval in USA and UK.

Keith began his research career as a PhD student at the University of Bath. He then held a Wellcome Trust Fellowship in Mental Health at Nottingham University Medical School in addition to a NATO Exchange Fellowship to Princeton University Psychology Department and has an extensive list of publications and patents.

Barbara Leyman, Ph.D. – Non-executive Director

Dr. Barbara Leyman joined LRM in 2014 and serves as a board member on the boards of Amakem, Complix, and Apitope. LRM is an investment company which develops and fosters economic growth in Limburg (Belgium).

Barbara has more than 10 years’ experience in the Biotechnology Industry. Before joining LRM, she was Business Development Manager at the Flanders Institute of Biotechnology (VIB), Belgium, where she was responsible for technology transfer. She initiated and managed multiple collaboration and licensing deals during her tenure at VIB.

From 1997 till 2005, Barbara followed a scientific career as a post-doc and project leader at Imperial College at Wye, University of London and K.U.Leuven.

Barbara holds a PhD. in molecular biology from the Imperial College at Wye, London University, UK, 1997 and a Master degree in Biotechnology from the University of Ghent, Belgium.

Brenig Preest – Non-executive Director

Brenig is an investment director at Excalibur in London and Cardiff. He is an experienced investor having completed over 30 investments. Brenig began his career at GE Healthcare, before joining PwC and then Ernst & Young as a corporate finance advisor. Most recently he was part of the venture capital team at Merchant Ventures where he was responsible for originating, structuring and managing investments. As an investor and advisor, Brenig has been involved in £0.5bn of transactions. Brenig studied pharmacology at Cardiff University and financial strategy at Oxford University, where he achieved a distinction. He is also a qualified chartered accountant.